478 related articles for article (PubMed ID: 31801360)
21. Adapter molecule DOC-2 is differentially expressed in pressure and volume overload hypertrophy and inhibits collagen synthesis in cardiac fibroblasts.
Kumbar DH; VanBergen A; Ocampo C; Muangmingsuk S; Griffin AJ; Gupta M
J Appl Physiol (1985); 2007 May; 102(5):2024-32. PubMed ID: 17255372
[TBL] [Abstract][Full Text] [Related]
22. Different roles of BAG3 in cardiac physiological hypertrophy and pathological remodeling.
Jia P; Wu N; Yang H; Guo Y; Guo X; Sun Y
Transl Res; 2021 Jul; 233():47-61. PubMed ID: 33578031
[TBL] [Abstract][Full Text] [Related]
23. The alteration of protein prenylation induces cardiomyocyte hypertrophy through Rheb-mTORC1 signalling and leads to chronic heart failure.
Xu N; Guan S; Chen Z; Yu Y; Xie J; Pan FY; Zhao NW; Liu L; Yang ZZ; Gao X; Xu B; Li CJ
J Pathol; 2015 Apr; 235(5):672-85. PubMed ID: 25385233
[TBL] [Abstract][Full Text] [Related]
24. Protective effects of endogenous adrenomedullin on cardiac hypertrophy, fibrosis, and renal damage.
Niu P; Shindo T; Iwata H; Iimuro S; Takeda N; Zhang Y; Ebihara A; Suematsu Y; Kangawa K; Hirata Y; Nagai R
Circulation; 2004 Apr; 109(14):1789-94. PubMed ID: 14967720
[TBL] [Abstract][Full Text] [Related]
25. Role of PDE10A in vascular smooth muscle cell hyperplasia and pathological vascular remodelling.
Luo L; Cai Y; Zhang Y; Hsu CG; Korshunov VA; Long X; Knight PA; Berk BC; Yan C
Cardiovasc Res; 2022 Sep; 118(12):2703-2717. PubMed ID: 34550322
[TBL] [Abstract][Full Text] [Related]
26. SENP1 Protects Against Pressure Overload-Induced Cardiac Remodeling and Dysfunction Via Inhibiting STAT3 Signaling.
Yang D; Fan D; Guo Z; Liu FY; Wang MY; An P; Yang Z; Tang QZ
J Am Heart Assoc; 2022 Nov; 11(22):e027004. PubMed ID: 36370010
[TBL] [Abstract][Full Text] [Related]
27. MG53, A Novel Regulator of KChIP2 and I
Liu W; Wang G; Zhang C; Ding W; Cheng W; Luo Y; Wei C; Liu J
Circulation; 2019 Apr; 139(18):2142-2156. PubMed ID: 30760025
[TBL] [Abstract][Full Text] [Related]
28. Cardiac hypertrophy is not amplified by deletion of cGMP-dependent protein kinase I in cardiomyocytes.
Lukowski R; Rybalkin SD; Loga F; Leiss V; Beavo JA; Hofmann F
Proc Natl Acad Sci U S A; 2010 Mar; 107(12):5646-51. PubMed ID: 20212138
[TBL] [Abstract][Full Text] [Related]
29. Ubiquitin-specific protease 19 blunts pathological cardiac hypertrophy via inhibition of the TAK1-dependent pathway.
Miao R; Lu Y; He X; Liu X; Chen Z; Wang J
J Cell Mol Med; 2020 Sep; 24(18):10946-10957. PubMed ID: 32798288
[TBL] [Abstract][Full Text] [Related]
30. Single-Cell Reconstruction of Progression Trajectory Reveals Intervention Principles in Pathological Cardiac Hypertrophy.
Ren Z; Yu P; Li D; Li Z; Liao Y; Wang Y; Zhou B; Wang L
Circulation; 2020 May; 141(21):1704-1719. PubMed ID: 32098504
[TBL] [Abstract][Full Text] [Related]
31. Loss of Apelin Augments Angiotensin II-Induced Cardiac Dysfunction and Pathological Remodeling.
Sato T; Kadowaki A; Suzuki T; Ito H; Watanabe H; Imai Y; Kuba K
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30634441
[TBL] [Abstract][Full Text] [Related]
32. Plasminogen Activator Inhibitor Type I Controls Cardiomyocyte Transforming Growth Factor-β and Cardiac Fibrosis.
Flevaris P; Khan SS; Eren M; Schuldt AJT; Shah SJ; Lee DC; Gupta S; Shapiro AD; Burridge PW; Ghosh AK; Vaughan DE
Circulation; 2017 Aug; 136(7):664-679. PubMed ID: 28588076
[TBL] [Abstract][Full Text] [Related]
33. Pathological cardiac hypertrophy alters intracellular targeting of phosphodiesterase type 5 from nitric oxide synthase-3 to natriuretic peptide signaling.
Zhang M; Takimoto E; Lee DI; Santos CX; Nakamura T; Hsu S; Jiang A; Nagayama T; Bedja D; Yuan Y; Eaton P; Shah AM; Kass DA
Circulation; 2012 Aug; 126(8):942-51. PubMed ID: 22829024
[TBL] [Abstract][Full Text] [Related]
34. Klotho inhibits angiotensin II-induced cardiac hypertrophy, fibrosis, and dysfunction in mice through suppression of transforming growth factor-β1 signaling pathway.
Ding J; Tang Q; Luo B; Zhang L; Lin L; Han L; Hao M; Li M; Yu L; Li M
Eur J Pharmacol; 2019 Sep; 859():172549. PubMed ID: 31325434
[TBL] [Abstract][Full Text] [Related]
35. Partial inhibition of activin receptor-like kinase 4 attenuates pressure overload-induced cardiac fibrosis and improves cardiac function.
Li CY; Chen YH; Wang Q; Hou JW; Wang H; Wang YP; Li YG
J Hypertens; 2016 Sep; 34(9):1766-77. PubMed ID: 27379535
[TBL] [Abstract][Full Text] [Related]
36. Cyclic nucleotide phosphodiesterases as therapeutic targets in cardiac hypertrophy and heart failure.
Kamel R; Leroy J; Vandecasteele G; Fischmeister R
Nat Rev Cardiol; 2023 Feb; 20(2):90-108. PubMed ID: 36050457
[TBL] [Abstract][Full Text] [Related]
37. The scaffold protein muscle A-kinase anchoring protein β orchestrates cardiac myocyte hypertrophic signaling required for the development of heart failure.
Kritzer MD; Li J; Passariello CL; Gayanilo M; Thakur H; Dayan J; Dodge-Kafka K; Kapiloff MS
Circ Heart Fail; 2014 Jul; 7(4):663-72. PubMed ID: 24812305
[TBL] [Abstract][Full Text] [Related]
38. Ubiquitin-Specific Protease 4 Is an Endogenous Negative Regulator of Pathological Cardiac Hypertrophy.
He B; Zhao YC; Gao LC; Ying XY; Xu LW; Su YY; Ji QQ; Lin N; Pu J
Hypertension; 2016 Jun; 67(6):1237-48. PubMed ID: 27045030
[TBL] [Abstract][Full Text] [Related]
39. Gene expression profiling of hypertrophic cardiomyocytes identifies new players in pathological remodelling.
Vigil-Garcia M; Demkes CJ; Eding JEC; Versteeg D; de Ruiter H; Perini I; Kooijman L; Gladka MM; Asselbergs FW; Vink A; Harakalova M; Bossu A; van Veen TAB; Boogerd CJ; van Rooij E
Cardiovasc Res; 2021 May; 117(6):1532-1545. PubMed ID: 32717063
[TBL] [Abstract][Full Text] [Related]
40. Phosphodiesterase 10A upregulation contributes to pulmonary vascular remodeling.
Tian X; Vroom C; Ghofrani HA; Weissmann N; Bieniek E; Grimminger F; Seeger W; Schermuly RT; Pullamsetti SS
PLoS One; 2011 Apr; 6(4):e18136. PubMed ID: 21494592
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
